Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.72 |
| ▸ | ITGB2 | P05107 | 4/20 | 0.72 |
| ▸ | ICAM1 | P05362 | 4/20 | 0.72 |
| ▸ | ITGAL | P20701 | 4/20 | 0.72 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.71 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.71 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.71 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.71 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.71 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.71 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.71 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.67 |
| ▸ | CA1 | P00915 | 1/20 | 0.67 |
| ▸ | CA9 | Q16790 | 1/20 | 0.67 |
| ▸ | TACR1 | P25103 | 3/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11875059 | 1.00 | ERAP2 (0.72) | ERAP2ITGB2ICAM1ITGALHDAC8 | |
| SCHEMBL11864161 | 1.00 | ERAP2 (0.72) | ERAP2ITGB2ICAM1ITGALHDAC8 | |
| Oxalic Acid SCHEMBL11878751 | 0.98 | ERAP2 (0.70) | ERAP2ITGB2ICAM1ITGALHDAC8 | |
| SCHEMBL30616778 | 0.92 | ITGB2 (0.78) | ERAP2ITGB2ICAM1ITGALCA12 | |
| SCHEMBL5191302 | 0.92 | ITGB2 (0.78) | ERAP2ITGB2ICAM1ITGALCA12 | |
| SCHEMBL5259129 | 0.92 | ITGB2 (0.78) | ERAP2ITGB2ICAM1ITGALCA12 | |
| SCHEMBL9466705 | 0.92 | ITGB2 (0.78) | ERAP2ITGB2ICAM1ITGALCA12 | |
| SCHEMBL11870861 | 0.91 | ERAP2 (0.76) | ERAP2ITGB2ICAM1ITGALCA12 | |
| SCHEMBL22206878 | 0.90 | ITGB2 (0.77) | ERAP2ITGB2ICAM1ITGALCA12 | |
| SCHEMBL22206876 | 0.90 | ITGB2 (0.77) | ERAP2ITGB2ICAM1ITGALCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204497-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2022-06-30 | — | — | US | claimed |
| EP-3939968-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | Medicinal Bioconvergence Research Center (KR) | 2022-01-19 | — | — | EP | claimed |
| WO-2020204548-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | 재단법인 의약바이오컨버젼스연구단 | 2020-10-08 | — | — | WO | claimed |
| US-20220204497-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2022-06-30 | — | — | US | disclosed |
| EP-3939968-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | Medicinal Bioconvergence Research Center (KR) | 2022-01-19 | — | — | EP | disclosed |
| WO-2020204548-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | 재단법인 의약바이오컨버젼스연구단 | 2020-10-08 | — | — | WO | disclosed |
| WO-2020014726-A1 | TREATMENT FOR LIVER REGENERATION | XENEXUS PHARMACEUTICALS PTY. LTD. (AU) | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204497-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | TPX2, AIMP2, CDYL2 | ERAP2 95/4885ITGB2 2981/4885ICAM1 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.